US2056046A
(en)
|
1933-05-19 |
1936-09-29 |
Rhone Poulenc Sa |
Manufacture of bases derived from benz-dioxane
|
US2375138A
(en)
|
1942-05-01 |
1945-05-01 |
American Cyanamid Co |
Alkamine esters of aryloxymethyl benzoic acid
|
US2629736A
(en)
|
1951-02-24 |
1953-02-24 |
Searle & Co |
Basically substituted n-alkyl derivatives of alpha, beta, beta-triarylpropionamides
|
US2730544A
(en)
|
1952-07-23 |
1956-01-10 |
Sahyun Lab |
Alkylaminoalkyl esters of hydroxycyclohexylbenzoic acid
|
US2750387A
(en)
|
1953-11-25 |
1956-06-12 |
Searle & Co |
Basically substituted derivatives of diarylaminobenzamides
|
DE1211359B
(de)
|
1955-11-29 |
1966-02-24 |
Oreal |
Oxydationsmittelfreies Kaltfaerbemittel fuer menschliches Haar
|
US2928833A
(en)
|
1959-03-03 |
1960-03-15 |
S E Massengill Company |
Theophylline derivatives
|
US3174901A
(en)
|
1963-01-31 |
1965-03-23 |
Jan Marcel Didier Aron Samuel |
Process for the oral treatment of diabetes
|
US3454635A
(en)
|
1965-07-27 |
1969-07-08 |
Hoechst Ag |
Benzenesulfonyl-ureas and process for their manufacture
|
DE1914999A1
(de)
|
1968-04-04 |
1969-11-06 |
Ciba Geigy |
Neue Guanylhydrazone und Verfahren zu ihrer Herstellung
|
ES385302A1
(es)
|
1970-10-22 |
1973-04-16 |
Miquel S A Lab |
Procedimiento para la obtencion de derivados trisubstitui- dos de etilendiamina.
|
NL167151C
(nl)
|
1971-04-09 |
1981-11-16 |
Acf Chemiefarma Nv |
Werkwijze ter bereiding van geneesmiddelen met anti-parasitaire werking op basis van halogeen bevatten- de 2,2'-methyleendifenolderivaten, alsmede werkwijze ter bereiding van deze geneeskrachtige verbindingen.
|
DE2205815A1
(de)
|
1972-02-08 |
1973-08-16 |
Hoechst Ag |
Piperazinderivate und verfahren zu ihrer herstellung
|
JPS5512435B2
(es)
|
1972-07-01 |
1980-04-02 |
|
|
US4005208A
(en)
|
1975-05-16 |
1977-01-25 |
Smithkline Corporation |
N-Heterocyclic-9-xanthenylamines
|
US4061753A
(en)
|
1976-02-06 |
1977-12-06 |
Interx Research Corporation |
Treating psoriasis with transient pro-drug forms of xanthine derivatives
|
NO154918C
(no)
|
1977-08-27 |
1987-01-14 |
Bayer Ag |
Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin.
|
DE2758025A1
(de)
|
1977-12-24 |
1979-07-12 |
Bayer Ag |
Neue derivate von 3,4,5-trihydroxypiperidin, verfahren zu ihrer herstellung und ihre verwendung
|
DE2929596A1
(de)
|
1979-07-21 |
1981-02-05 |
Hoechst Ag |
Verfahren zur herstellung von oxoalkyl-xanthinen
|
DE2951135A1
(de)
|
1979-12-19 |
1981-06-25 |
Hoechst Ag, 6230 Frankfurt |
Sulfonylharnstoffe, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung
|
JPS5639056A
(en)
|
1980-07-16 |
1981-04-14 |
Kanebo Ltd |
Preparation of n,n,n',n'-tetraacylated nucleus halogenated aromatic diamine
|
GB2084580B
(en)
|
1980-10-01 |
1984-07-04 |
Glaxo Group Ltd |
Aminoalkyl furan derivative
|
US4382091A
(en)
|
1981-04-30 |
1983-05-03 |
Syntex (U.S.A.) Inc. |
Stabilization of 1-substituted imidazole derivatives in talc
|
JPS58164502A
(ja)
|
1982-03-26 |
1983-09-29 |
Chugai Pharmaceut Co Ltd |
除草用組成物
|
FR2558162B1
(fr)
|
1984-01-17 |
1986-04-25 |
Adir |
Nouveaux derives de la xanthine, leurs procedes de preparation et les compositions pharmaceutiques les renfermant
|
FI79107C
(fi)
|
1984-06-25 |
1989-11-10 |
Orion Yhtymae Oy |
Foerfarande foer framstaellning av stabil -form av prazosinhydroklorid.
|
AR240698A1
(es)
|
1985-01-19 |
1990-09-28 |
Takeda Chemical Industries Ltd |
Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
|
US4786755A
(en)
|
1985-06-03 |
1988-11-22 |
Warner-Lambert Company |
Diphenic acid monoamides
|
US4602023A
(en)
|
1985-06-03 |
1986-07-22 |
Warner-Lambert Company |
Diphenic acid monoamides
|
GB8515934D0
(en)
|
1985-06-24 |
1985-07-24 |
Janssen Pharmaceutica Nv |
(4-piperidinomethyl and-hetero)purines
|
US5258380A
(en)
|
1985-06-24 |
1993-11-02 |
Janssen Pharmaceutica N.V. |
(4-piperidinylmethyl and -hetero)purines
|
EP0223403B1
(en)
|
1985-10-25 |
1993-08-04 |
Beecham Group Plc |
Piperidine derivative, its preparation, and its use as medicament
|
US5433959A
(en)
|
1986-02-13 |
1995-07-18 |
Takeda Chemical Industries, Ltd. |
Stabilized pharmaceutical composition
|
ATE72244T1
(de)
|
1986-03-21 |
1992-02-15 |
Heumann Pharma Gmbh & Co |
Kristalline, wasserfreie sigma -form von 2-(4-(2furoyl-(2-piperazin)-1-yl>-4-amino-6,7- dimethoxychinazolinhydrochlorid und verfahren zu ihrer herstellung.
|
EP1498425A1
(en)
|
1986-05-05 |
2005-01-19 |
The General Hospital Corporation |
Use of glucagone-like-peptide 1 (GLP-1) derivatives for the preparation of pharmaceutical compositions
|
AU619444B2
(en)
|
1986-06-02 |
1992-01-30 |
Nippon Chemiphar Co. Ltd. |
2-(2-aminobenzylsulfinyl)- benzimidazole derivatives
|
US4802924A
(en)
*
|
1986-06-19 |
1989-02-07 |
Colorcon, Inc. |
Coatings based on polydextrose for aqueous film coating of pharmaceutical food and confectionary products
|
US4968672A
(en)
|
1987-01-02 |
1990-11-06 |
The United States Of America As Represented By The Department Of Health And Human Services |
Adenosine receptor prodrugs
|
US4743450A
(en)
|
1987-02-24 |
1988-05-10 |
Warner-Lambert Company |
Stabilized compositions
|
JPS6440433A
(en)
|
1987-08-05 |
1989-02-10 |
Green Cross Corp |
Aqueous liquid composition of thrombin
|
US4786023A
(en)
|
1987-08-19 |
1988-11-22 |
Harris Leverett D |
Drafting implement holder
|
ATE117685T1
(de)
|
1988-05-19 |
1995-02-15 |
Chugai Pharmaceutical Co Ltd |
Chinoloncarbonsäure-derivate.
|
US5329025A
(en)
|
1988-09-21 |
1994-07-12 |
G. D. Searle & Co. |
3-azido compound
|
US5234897A
(en)
|
1989-03-15 |
1993-08-10 |
Bayer Aktiengesellschaft |
Herbicidal 3-amino-5-aminocarbonyl-1,2,4-triazoles
|
DE3926119A1
(de)
|
1989-08-08 |
1991-02-14 |
Bayer Ag |
3-amino-5-aminocarbonyl-1,2,4-triazol-derivate
|
GB8906792D0
(en)
|
1989-03-23 |
1989-05-10 |
Beecham Wuelfing Gmbh & Co Kg |
Treatment and compounds
|
DE3916430A1
(de)
|
1989-05-20 |
1990-11-22 |
Bayer Ag |
Verfahren zur herstellung von 3-amino-5-aminocarbonyl-1,2,4-triazol-derivaten
|
US5332744A
(en)
|
1989-05-30 |
1994-07-26 |
Merck & Co., Inc. |
Substituted imidazo-fused 6-membered heterocycles as angiotensin II antagonists
|
US5223499A
(en)
|
1989-05-30 |
1993-06-29 |
Merck & Co., Inc. |
6-amino substituted imidazo[4,5-bipyridines as angiotensin II antagonists
|
IL94390A
(en)
|
1989-05-30 |
1996-03-31 |
Merck & Co Inc |
The 6-membered trans-nitrogen-containing heterocycles are compressed with imidazo and pharmaceutical preparations containing them
|
FI94339C
(fi)
|
1989-07-21 |
1995-08-25 |
Warner Lambert Co |
Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
|
HU208115B
(en)
|
1989-10-03 |
1993-08-30 |
Biochemie Gmbh |
New process for producting pleuromutilin derivatives
|
FR2654935B1
(fr)
|
1989-11-28 |
1994-07-01 |
Lvmh Rech |
Utilisation de xanthines, eventuellement incorporees dans des liposomes, pour favoriser la pigmentation de la peau ou des cheveux.
|
DE122007000050I1
(de)
|
1990-02-19 |
2007-11-08 |
Novartis Ag |
Acylverbindungen
|
KR930000861B1
(ko)
|
1990-02-27 |
1993-02-08 |
한미약품공업 주식회사 |
오메프라졸 직장투여 조성물
|
DK0475482T3
(da)
|
1990-09-13 |
1995-04-03 |
Akzo Nobel Nv |
Stabiliserede faste kemiske midler
|
GB9020959D0
(en)
|
1990-09-26 |
1990-11-07 |
Beecham Group Plc |
Novel compounds
|
US5084460A
(en)
|
1990-12-24 |
1992-01-28 |
A. H. Robins Company, Incorporated |
Methods of therapeutic treatment with N-(3-ouinuclidinyl)-2-hydroxybenzamides and thiobenzamides
|
US5602127A
(en)
|
1991-02-06 |
1997-02-11 |
Karl Thomae Gmbh |
(Alkanesultam-1-yl)-benzimidazol-1-yl)-1yl)-methyl-biphenyls useful as angiotensin-II antagonists
|
US5614519A
(en)
|
1991-02-06 |
1997-03-25 |
Karl Thomae Gmbh |
(1-(2,3 or 4-N-morpholinoalkyl)-imidazol-4-yl)-benizimidazol-1-yl-methyl]-biphenyls useful as angiotensin-II antagonists
|
US5594003A
(en)
|
1991-02-06 |
1997-01-14 |
Dr. Karl Thomae Gmbh |
Tetrahydroimidazo[1,2-a]pyridin-2-yl-(benzimidazol-1-yl)-methyl-biphenyls useful as angiotensin-II antagonists
|
GB9109862D0
(en)
|
1991-05-08 |
1991-07-03 |
Beecham Lab Sa |
Pharmaceutical formulations
|
DE4124150A1
(de)
|
1991-07-20 |
1993-01-21 |
Bayer Ag |
Substituierte triazole
|
US5300298A
(en)
|
1992-05-06 |
1994-04-05 |
The Pennsylvania Research Corporation |
Methods of treating obesity with purine related compounds
|
GB9215633D0
(en)
|
1992-07-23 |
1992-09-09 |
Smithkline Beecham Plc |
Novel treatment
|
DE69318077T2
(de)
|
1992-07-31 |
1998-10-29 |
Shionogi & Co |
Triazolylthiomethylthiocephalosporin-Hydrochlorid, sein kristallines Hydrat und seine Herstellung
|
TW252044B
(es)
|
1992-08-10 |
1995-07-21 |
Boehringer Ingelheim Kg |
|
DE4242459A1
(de)
|
1992-12-16 |
1994-06-23 |
Merck Patent Gmbh |
Imidazopyridine
|
EP0638567A4
(en)
|
1993-02-18 |
1995-05-10 |
Kyowa Hakko Kogyo Kk |
ADENOSINE INHIBITORS.
|
FR2707641B1
(fr)
|
1993-07-16 |
1995-08-25 |
Fournier Ind & Sante |
Composés de l'imidazol-5-carboxamide, leur procédé de préparation leurs intermédiaires et leur utilisation en thérapeutique.
|
DE4339868A1
(de)
|
1993-11-23 |
1995-05-24 |
Merck Patent Gmbh |
Imidazopyridazine
|
DE4404183A1
(de)
|
1994-02-10 |
1995-08-17 |
Merck Patent Gmbh |
4-Amino-1-piperidylbenzoylguanidine
|
US5545745A
(en)
|
1994-05-23 |
1996-08-13 |
Sepracor, Inc. |
Enantioselective preparation of optically pure albuterol
|
CO4410190A1
(es)
|
1994-09-19 |
1997-01-09 |
Lilly Co Eli |
3-[4-(2-AMINOETOXI)-BENZOIL]-2-ARIL-6-HIDROXIBENZO [b] TIOFENO CRISTALINO
|
ATE248153T1
(de)
|
1994-10-12 |
2003-09-15 |
Euro Celtique Sa |
Neue benzoxazole
|
GB9501178D0
(en)
|
1995-01-20 |
1995-03-08 |
Wellcome Found |
Guanine derivative
|
CA2218548A1
(en)
|
1995-05-19 |
1996-11-21 |
Chiroscience Limited |
Xanthines and their therapeutic use
|
GB9523752D0
(en)
|
1995-11-21 |
1996-01-24 |
Pfizer Ltd |
Pharmaceutical formulations
|
DE19543478A1
(de)
|
1995-11-22 |
1997-05-28 |
Bayer Ag |
Kristallines Hydrochlorid von {(R)-(-)-2- N-[4-(1,1-Dioxido-3-oxo-2,3-dihydrobenzisothiazol-2-yl)-buytl]-aminomethyl}-chroman
|
FR2742751B1
(fr)
|
1995-12-22 |
1998-01-30 |
Rhone Poulenc Rorer Sa |
Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
|
CN1209117A
(zh)
|
1995-12-26 |
1999-02-24 |
奥尔顿有限公司 |
N-酰氨基烷基肼亚氨酰胺
|
DE19616486C5
(de)
|
1996-04-25 |
2016-06-30 |
Royalty Pharma Collection Trust |
Verfahren zur Senkung des Blutglukosespiegels in Säugern
|
AU1153097A
(en)
|
1996-06-07 |
1998-01-05 |
Eisai Co. Ltd. |
Stable polymorphs of donepezil (1-benzyl-4-{(5,6-dimethoxy-1-indanon)-2-yl}methylpiperidine ) hydrochloride and process for production
|
US5965555A
(en)
|
1996-06-07 |
1999-10-12 |
Hoechst Aktiengesellschaft |
Xanthine compounds having terminally animated alkynol side chains
|
US5958951A
(en)
|
1996-06-14 |
1999-09-28 |
Novo Nordiskials |
Modified form of the R(-)-N-(4,4-di(3-methylthien-2-yl)but-3-enyl)-nipecotic acid hydrochloride
|
US5753635A
(en)
|
1996-08-16 |
1998-05-19 |
Berlex Laboratories, Inc. |
Purine derivatives and their use as anti-coagulants
|
CA2266444C
(en)
|
1996-09-23 |
2007-01-09 |
Eli Lilly And Company |
Olanzapine dihydrate d
|
WO1998018770A1
(en)
|
1996-10-28 |
1998-05-07 |
Novo Nordisk A/S |
A process for the preparation of (-)-3,4-trans-diarylchromans
|
UA65549C2
(uk)
|
1996-11-05 |
2004-04-15 |
Елі Ліллі Енд Компані |
Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
|
DE69732572T2
(de)
|
1996-11-12 |
2005-12-29 |
Novo Nordisk A/S |
Verwendung von glp-1 peptiden
|
GB9623859D0
(en)
|
1996-11-15 |
1997-01-08 |
Chiroscience Ltd |
Novel compounds
|
SK284989B6
(sk)
|
1996-12-24 |
2006-04-06 |
Biogen, Inc. |
Kvapalná kompozícia obsahujúca interferón a spôsob stabilizácie interferónu
|
AU729614B2
(en)
*
|
1997-01-06 |
2001-02-08 |
Bpsi Holdings, Inc. |
Film coatings and film coating compositions based on dextrin
|
AU6024998A
(en)
|
1997-01-15 |
1998-08-07 |
Glycomed Incorporated |
Aryl c-glycoside compounds and sulfated esters thereof
|
DE19705233A1
(de)
|
1997-02-12 |
1998-08-13 |
Froelich Juergen C |
Verfahren zur Herstellung einer Formulierung enthaltend Arginin
|
US6011049A
(en)
|
1997-02-19 |
2000-01-04 |
Warner-Lambert Company |
Combinations for diabetes
|
NZ337592A
(en)
|
1997-03-13 |
2001-01-26 |
Hexal Ag |
Stabilization of acid sensitive benzimidazoles with amino/cyclodextrin combinations
|
US5972332A
(en)
|
1997-04-16 |
1999-10-26 |
The Regents Of The University Of Michigan |
Wound treatment with keratinocytes on a solid support enclosed in a porous material
|
US6635280B2
(en)
|
1997-06-06 |
2003-10-21 |
Depomed, Inc. |
Extending the duration of drug release within the stomach during the fed mode
|
PT998271E
(pt)
|
1997-06-06 |
2005-10-31 |
Depomed Inc |
Formas de dosagem oral de farmacos com retencao gastrica para a libertacao controlada de farmacos altamente soluveis
|
PE79099A1
(es)
|
1997-06-13 |
1999-08-24 |
Lilly Co Eli |
Formulaciones de insulina estables
|
JPH11124392A
(ja)
|
1997-10-21 |
1999-05-11 |
Sankyo Co Ltd |
C−グリコシル化されたアリールスズ化合物
|
MXPA00005506A
(es)
|
1997-12-05 |
2008-09-11 |
Astrazeneca Uk Ltd |
Compuestos novedosos.
|
ID21411A
(id)
|
1997-12-10 |
1999-06-10 |
Takeda Chemical Industries Ltd |
Agen untuk mengobati daya tahan glukosa yang berisiko tinggi rusak
|
JPH11193270A
(ja)
|
1997-12-26 |
1999-07-21 |
Koei Chem Co Ltd |
光学活性1−メチル−3−ピペリジンメタノールの製造方法
|
ATE242775T1
(de)
|
1998-01-05 |
2003-06-15 |
Eisai Co Ltd |
Purinderivate und antagonisten des adenosin-a2- rezeptors, welche zur vorsorge oder heilung von diabetes dienen
|
CA2319195A1
(en)
|
1998-02-02 |
1999-08-05 |
Trustees Of Tufts College |
Method of regulating glucose metabolism, and reagents related thereto
|
JP4523153B2
(ja)
|
1998-03-19 |
2010-08-11 |
ブリストル−マイヤーズ スクイブ カンパニー |
易溶性薬物の二層性放出制御送達システムおよび方法
|
US6099859A
(en)
|
1998-03-20 |
2000-08-08 |
Andrx Pharmaceuticals, Inc. |
Controlled release oral tablet having a unitary core
|
EP1066265A1
(en)
|
1998-03-31 |
2001-01-10 |
Nissan Chemical Industries, Ltd. |
Pyridazinone hydrochloride compound and method for producing the same
|
EP0950658A1
(en)
|
1998-04-13 |
1999-10-20 |
Takeda Chemical Industries, Ltd. |
2-Pipirazinone-1-acetic acid dihydrochloride derivative used to inhibit platelet aggregation
|
US6207207B1
(en)
|
1998-05-01 |
2001-03-27 |
Mars, Incorporated |
Coated confectionery having a crispy starch based center and method of preparation
|
DE19823831A1
(de)
|
1998-05-28 |
1999-12-02 |
Probiodrug Ges Fuer Arzneim |
Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
|
DE19828114A1
(de)
|
1998-06-24 |
2000-01-27 |
Probiodrug Ges Fuer Arzneim |
Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
|
CO5150173A1
(es)
|
1998-12-10 |
2002-04-29 |
Novartis Ag |
Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
|
US6613806B1
(en)
|
1999-01-29 |
2003-09-02 |
Basf Corporation |
Enhancement of the efficacy of benzoylbenzenes
|
IT1312018B1
(it)
|
1999-03-19 |
2002-04-04 |
Fassi Aldo |
Procedimento migliorato per la produzione di sali non igroscopicidella l(-)-carnitina.
|
EP1177797A1
(en)
|
1999-05-12 |
2002-02-06 |
Fujisawa Pharmaceutical Co., Ltd. |
Novel use
|
US20040152659A1
(en)
|
1999-05-12 |
2004-08-05 |
Fujisawa Pharmaceutical Co. Ltd. |
Method for the treatment of parkinson's disease comprising administering an A1A2a receptor dual antagonist
|
AU5294100A
(en)
|
1999-05-27 |
2000-12-18 |
University Of Virginia Patent Foundation |
Method and compositions for treating the inflammatory response
|
US6545002B1
(en)
|
1999-06-01 |
2003-04-08 |
University Of Virginia Patent Foundation |
Substituted 8-phenylxanthines useful as antagonists of A2B adenosine receptors
|
UA71976C2
(en)
|
1999-06-21 |
2005-01-17 |
Boehringer Ingelheim Pharma |
Bicyclic heterocycles and a medicament based thereon
|
US6448323B1
(en)
*
|
1999-07-09 |
2002-09-10 |
Bpsi Holdings, Inc. |
Film coatings and film coating compositions based on polyvinyl alcohol
|
ES2166270B1
(es)
|
1999-07-27 |
2003-04-01 |
Almirall Prodesfarma Sa |
Derivados de 8-fenil-6,9-dihidro-(1,2,4,)triazolo(3,4-i)purin-5-ona.
|
DK1213296T3
(da)
|
1999-08-31 |
2004-08-16 |
Kissei Pharmaceutical |
Glucopyranosyloxpyrazolderivater, lægemidler indeholdende samme samt mellemprodukter til fremstilling heraf
|
PH12000002657B1
(en)
|
1999-10-12 |
2006-02-21 |
Bristol Myers Squibb Co |
C-aryl glucoside SGLT2 inhibitors
|
US6515117B2
(en)
|
1999-10-12 |
2003-02-04 |
Bristol-Myers Squibb Company |
C-aryl glucoside SGLT2 inhibitors and method
|
US6586438B2
(en)
|
1999-11-03 |
2003-07-01 |
Bristol-Myers Squibb Co. |
Antidiabetic formulation and method
|
GB9928330D0
(en)
|
1999-11-30 |
2000-01-26 |
Ferring Bv |
Novel antidiabetic agents
|
KR20020063260A
(ko)
|
1999-12-23 |
2002-08-01 |
노파르티스 아게 |
당 대사 장애를 치료하기 위한 혈당강하제의 용도
|
JP2003519698A
(ja)
|
2000-01-07 |
2003-06-24 |
トランスフォーム ファーマスーティカルズ,インコーポレイテッド |
多様な固体形態のハイスループットでの形成、同定および分析
|
US6362172B2
(en)
|
2000-01-20 |
2002-03-26 |
Bristol-Myers Squibb Company |
Water soluble prodrugs of azole compounds
|
DE122008000018I1
(de)
|
2000-01-21 |
2008-08-14 |
Novartis Pharma Ag |
Zusammensetzungen bestehend aus Dipeptidylpeptidase-IV Inhibitoren und Antidiabetica
|
JP4621326B2
(ja)
|
2000-02-01 |
2011-01-26 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
テプレノンの安定化組成物
|
US6627611B2
(en)
|
2000-02-02 |
2003-09-30 |
Kotobuki Pharmaceutical Co Ltd |
C-glycosides and preparation of thereof as antidiabetic agents
|
JP4456768B2
(ja)
|
2000-02-02 |
2010-04-28 |
壽製薬株式会社 |
C−配糖体を含有する薬剤
|
AU782878B2
(en)
|
2000-02-05 |
2005-09-08 |
Vertex Pharmaceuticals Incorporated |
Pyrazole compositions useful as inhibitors of erk
|
WO2001062295A1
(fr)
|
2000-02-24 |
2001-08-30 |
Takeda Chemical Industries, Ltd. |
Medicaments contenant des ingredients actifs combines
|
EP1132389A1
(en)
|
2000-03-06 |
2001-09-12 |
Vernalis Research Limited |
New aza-indolyl derivatives for the treatment of obesity
|
US6395767B2
(en)
|
2000-03-10 |
2002-05-28 |
Bristol-Myers Squibb Company |
Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
|
GB0006133D0
(en)
|
2000-03-14 |
2000-05-03 |
Smithkline Beecham Plc |
Novel pharmaceutical
|
GT200100039A
(es)
*
|
2000-03-16 |
2001-12-31 |
Pfizer |
Inhibidor de la glucogeno fosforilasa.
|
JP2001278812A
(ja)
|
2000-03-27 |
2001-10-10 |
Kyoto Pharmaceutical Industries Ltd |
錠剤用崩壊剤及びこれを用いた錠剤
|
US6683056B2
(en)
|
2000-03-30 |
2004-01-27 |
Bristol-Myers Squibb Company |
O-aryl glucoside SGLT2 inhibitors and method
|
WO2001072290A2
(en)
|
2000-03-31 |
2001-10-04 |
Probiodrug Ag |
Method for the improvement of islet signaling in diabetes mellitus and for its prevention
|
JP2001292388A
(ja)
|
2000-04-05 |
2001-10-19 |
Sharp Corp |
再生装置
|
GB0008694D0
(en)
|
2000-04-07 |
2000-05-31 |
Novartis Ag |
Organic compounds
|
EP1295873A4
(en)
|
2000-06-14 |
2004-05-19 |
|
METHODS OF PRODUCING RACEMIC PIPERIDINE DERIVATIVE AND PRODUCING OPTICALLY ACTIVE PIPERIDINE DERIVATIVE
|
GB0014969D0
(en)
|
2000-06-19 |
2000-08-09 |
Smithkline Beecham Plc |
Novel method of treatment
|
US7078397B2
(en)
|
2000-06-19 |
2006-07-18 |
Smithkline Beecham Corporation |
Combinations of dipeptidyl peptidase IV inhibitors and other antidiabetic agents for the treatment of diabetes mellitus
|
US6488962B1
(en)
|
2000-06-20 |
2002-12-03 |
Depomed, Inc. |
Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
|
PL360856A1
(en)
|
2000-07-04 |
2004-09-20 |
Novo Nordisk A/S |
Purine-2,6-diones which are inhibitors of the enzyme dipeptidyl peptidase iv (dpp-iv)
|
NZ524618A
(en)
|
2000-08-10 |
2004-08-27 |
Mitsubishi Pharma Corp |
Proline derivatives and use thereof as drugs
|
US6821978B2
(en)
|
2000-09-19 |
2004-11-23 |
Schering Corporation |
Xanthine phosphodiesterase V inhibitors
|
SK287811B6
(sk)
|
2000-09-29 |
2011-10-04 |
Kissei Pharmaceutical Co., Ltd |
Glukopyranozyloxybenzylbenzénový derivát, farmaceutická kompozícia a ľudský SGLT2-inhibítor tento derivát obsahujúci a použitie tohto derivátu
|
US6790459B1
(en)
|
2000-11-03 |
2004-09-14 |
Andrx Labs, Llc |
Methods for treating diabetes via administration of controlled release metformin
|
US20060034922A1
(en)
|
2000-11-03 |
2006-02-16 |
Andrx Labs, Llc |
Controlled release metformin compositions
|
US6866866B1
(en)
|
2000-11-03 |
2005-03-15 |
Andrx Labs, Llc |
Controlled release metformin compositions
|
US7053060B2
(en)
|
2000-11-30 |
2006-05-30 |
Kissei Pharmaceutical Co., Ltd. |
Glucopyranosyloxybenzylbenzene derivatives, medicinal compositions containing the same and intermediates in the production thereof
|
EP1354882A1
(en)
|
2000-12-27 |
2003-10-22 |
Kyowa Hakko Kogyo Co., Ltd. |
Dipeptidyl peptidase iv inhibitor
|
BRPI0116607B8
(pt)
|
2000-12-28 |
2021-05-25 |
Kissei Pharmaceutical |
derivados de glicopiranosiloxipirazol , composições farmacêuticas que os contêm e usos dos mesmos
|
FR2819254B1
(fr)
|
2001-01-08 |
2003-04-18 |
Fournier Lab Sa |
Nouveaux composes de la n-(phenylsulfonyl) glycine, leur procede de preparation et leur utilisation pour obtenir des compostions pharmaceutiques
|
DE10117803A1
(de)
|
2001-04-10 |
2002-10-24 |
Boehringer Ingelheim Pharma |
Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
|
DE10109021A1
(de)
|
2001-02-24 |
2002-09-05 |
Boehringer Ingelheim Pharma |
Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
|
SK10802003A3
(sk)
|
2001-02-02 |
2004-05-04 |
Takeda Chemical Industries, Ltd. |
Kondenzovaná heterocyklická zlúčenina, jej použitie a jej farmaceutický prípravok
|
TWI255817B
(en)
|
2001-02-14 |
2006-06-01 |
Kissei Pharmaceutical |
Glucopyranosyloxybenzylbenzene derivatives and medicinal use thereof
|
WO2002066015A1
(en)
|
2001-02-16 |
2002-08-29 |
Bristol-Myers Squibb Pharma Company |
Use of polyalkylamine polymers in controlled release devices
|
MEP59808A
(en)
|
2001-02-24 |
2011-05-10 |
Boehringer Ingelheim Pharma |
Xanthine derivative, production and use thereof as a medicament
|
US6936590B2
(en)
|
2001-03-13 |
2005-08-30 |
Bristol Myers Squibb Company |
C-aryl glucoside SGLT2 inhibitors and method
|
US6693094B2
(en)
|
2001-03-22 |
2004-02-17 |
Chrono Rx Llc |
Biguanide and sulfonylurea formulations for the prevention and treatment of insulin resistance and type 2 diabetes mellitus
|
JP3698067B2
(ja)
|
2001-03-30 |
2005-09-21 |
Jsr株式会社 |
電子吸引性基および電子供与性基を有するモノマー、それを用いた共重合体、ならびにプロトン伝導膜
|
HUP0600232A2
(en)
|
2001-04-11 |
2006-08-28 |
Bristol Myers Squibb Co |
Amino acid complexes of c-aryl glucosides for treatment of diabetes and method
|
JP2002348279A
(ja)
|
2001-05-25 |
2002-12-04 |
Nippon Kayaku Co Ltd |
光学活性ピリジルケトン誘導体の製造方法並びに光学活性ピリジルケトン誘導体
|
DE10130371A1
(de)
|
2001-06-23 |
2003-01-02 |
Boehringer Ingelheim Pharma |
Neue Arzneimittelkompositionen auf der Basis von Anticholinergika, Corticosteroiden und Betamimetika
|
GB0115517D0
(en)
|
2001-06-25 |
2001-08-15 |
Ferring Bv |
Novel antidiabetic agents
|
ES2339813T3
(es)
|
2001-06-27 |
2010-05-25 |
Glaxosmithkline Llc |
Fluoropirrolidinas como inhibidores de dipeptidil peptidasas.
|
ES2291477T3
(es)
|
2001-06-27 |
2008-03-01 |
Smithkline Beecham Corporation |
Fluoropirrolidinas como inhibidores de dipeptidil peptidasa.
|
US6869947B2
(en)
|
2001-07-03 |
2005-03-22 |
Novo Nordisk A/S |
Heterocyclic compounds that are inhibitors of the enzyme DPP-IV
|
JP2005502624A
(ja)
|
2001-07-03 |
2005-01-27 |
ノボ ノルディスク アクティーゼルスカブ |
糖尿病を治療するための、dpp−ivを阻害するプリン誘導体
|
UA74912C2
(en)
|
2001-07-06 |
2006-02-15 |
Merck & Co Inc |
Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
|
US7638522B2
(en)
|
2001-08-13 |
2009-12-29 |
Janssen Pharmaceutica N.V. |
Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
|
US20030087843A1
(en)
|
2001-09-05 |
2003-05-08 |
Washburn William N. |
O-pyrazole glucoside SGLT2 inhibitors and method of use
|
WO2003024965A2
(en)
|
2001-09-19 |
2003-03-27 |
Novo Nordisk A/S |
Heterocyclic compounds that are inhibitors of the enzyme dpp-iv
|
WO2003031458A1
(en)
|
2001-10-12 |
2003-04-17 |
Dana-Farber Cancer Institute |
Methods for synthesis of diarylmethanes
|
KR100679990B1
(ko)
|
2001-10-15 |
2007-02-08 |
헤모텍 게엠베하 |
재협착증의 방지를 위한 스텐트의 코팅
|
CA2463989C
(en)
|
2001-10-17 |
2012-01-31 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Pyrimidine derivatives, pharmaceutical compositions containing these compounds, the use thereof and process for the preparation thereof
|
DE10151296A1
(de)
|
2001-10-17 |
2003-04-30 |
Boehringer Ingelheim Pharma |
Keratinozyten verwendbar als biologisch aktive Substanz bei der Behandlung von Wunden
|
US6723340B2
(en)
|
2001-10-25 |
2004-04-20 |
Depomed, Inc. |
Optimal polymer mixtures for gastric retentive tablets
|
US6861440B2
(en)
|
2001-10-26 |
2005-03-01 |
Hoffmann-La Roche Inc. |
DPP IV inhibitors
|
US20030083354A1
(en)
|
2001-10-26 |
2003-05-01 |
Pediamed Pharmaceuticals, Inc. |
Phenylephrine tannate and pyrilamine tannate salts in pharmaceutical compositions
|
CA2363053C
(en)
|
2001-11-09 |
2011-01-25 |
Bernard Charles Sherman |
Clopidogrel bisulfate tablet formulation
|
WO2003053929A1
(fr)
|
2001-12-21 |
2003-07-03 |
Toray Fine Chemicals Co., Ltd. |
Procede de production de derives de cis-piperidine optiquement actifs
|
US6727261B2
(en)
|
2001-12-27 |
2004-04-27 |
Hoffman-La Roche Inc. |
Pyrido[2,1-A]Isoquinoline derivatives
|
EP1496877B1
(en)
|
2002-01-11 |
2008-10-01 |
Novo Nordisk A/S |
Method and composition for treatment of diabetes, hypertension, chronic heart failure and fluid retentive states
|
PT2260833E
(pt)
|
2002-01-16 |
2012-12-26 |
Boehringer Ingelheim Pharma |
Comprimido farmacêutico de duas camadas compreendendo telmisartan e um diurético
|
EP1333033A1
(en)
|
2002-01-30 |
2003-08-06 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
FAP-activated anti-tumor compounds
|
JP2005517690A
(ja)
|
2002-02-01 |
2005-06-16 |
ファイザー・プロダクツ・インク |
固体薬物分散物を含有する即時放出剤形
|
US7610153B2
(en)
|
2002-02-13 |
2009-10-27 |
Virginia Commonwealth University |
Multi-drug titration and evaluation
|
EP1476139B1
(en)
*
|
2002-02-21 |
2017-05-17 |
Valeant Pharmaceuticals Luxembourg S.à.r.l. |
Controlled release dosage forms
|
US7074798B2
(en)
|
2002-02-25 |
2006-07-11 |
Eisai Co., Ltd |
Xanthine derivative and DPPIV inhibitor
|
HUP0200849A2
(hu)
|
2002-03-06 |
2004-08-30 |
Sanofi-Synthelabo |
N-aminoacetil-2-ciano-pirrolidin-származékok, e vegyületeket tartalmazó gyógyszerkészítmények és eljárás előállításukra
|
GB0206215D0
(en)
|
2002-03-15 |
2002-05-01 |
Novartis Ag |
Organic compounds
|
JP4298212B2
(ja)
|
2002-03-29 |
2009-07-15 |
大日本印刷株式会社 |
塩酸エピナスチン高融点型結晶の製造法
|
JP2003300977A
(ja)
|
2002-04-10 |
2003-10-21 |
Sumitomo Pharmaceut Co Ltd |
キサンチン誘導体
|
US20050113577A1
(en)
|
2002-04-16 |
2005-05-26 |
Karki Shyam B. |
Solid forms of slats with tyrosine kinase activity
|
EP1500403A4
(en)
|
2002-04-26 |
2008-09-17 |
Ajinomoto Kk |
MEANS FOR THE PREVENTION / TREATMENT OF DIABETES
|
WO2003094909A2
(en)
|
2002-05-09 |
2003-11-20 |
Enos Pharmaceuticals, Inc. |
Methods and compositions for the treatment and prevention of intermittent claudication or alzheimer's disease
|
GB0212412D0
(en)
|
2002-05-29 |
2002-07-10 |
Novartis Ag |
Combination of organic compounds
|
CN101538224A
(zh)
|
2002-05-31 |
2009-09-23 |
先灵公司 |
制备黄嘌呤磷酸二酯酶v抑制剂及其前体的方法
|
AU2003241960B2
(en)
|
2002-06-06 |
2009-07-30 |
Eisai R&D Management Co., Ltd. |
Novel fused imidazole derivative
|
FR2840897B1
(fr)
|
2002-06-14 |
2004-09-10 |
Fournier Lab Sa |
Nouveaux derives d'arylsulfonamides et leur utilisation en therapeutique
|
US20040002615A1
(en)
|
2002-06-28 |
2004-01-01 |
Allen David Robert |
Preparation of chiral amino-nitriles
|
DE10231370B4
(de)
|
2002-07-11 |
2006-04-06 |
Sanofi-Aventis Deutschland Gmbh |
Thiophenglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
|
US20040023981A1
(en)
|
2002-07-24 |
2004-02-05 |
Yu Ren |
Salt forms with tyrosine kinase activity
|
TW200409746A
(en)
|
2002-07-26 |
2004-06-16 |
Theravance Inc |
Crystalline β2 adrenergic receptor agonist
|
TWI254635B
(en)
|
2002-08-05 |
2006-05-11 |
Yamanouchi Pharma Co Ltd |
Azulene derivative and salt thereof
|
ATE469161T1
(de)
|
2002-08-08 |
2010-06-15 |
Kissei Pharmaceutical |
Pyrazolderivat, dieses enthaltende medizinische zusammensetzung, medizinische verwendung davon, und zwischenprodukt für dessen herstellung
|
TW200404796A
(en)
|
2002-08-19 |
2004-04-01 |
Ono Pharmaceutical Co |
Nitrogen-containing compound
|
US7407955B2
(en)
|
2002-08-21 |
2008-08-05 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
|
DE10238243A1
(de)
|
2002-08-21 |
2004-03-04 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
|
CN105001222B
(zh)
|
2002-08-21 |
2017-11-07 |
勃林格殷格翰制药两合公司 |
8‑[3‑氨基‑哌啶‑1‑基]‑黄嘌呤化合物,其制备方法及作为药物制剂的用途
|
US7495005B2
(en)
|
2002-08-22 |
2009-02-24 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Xanthine derivatives, their preparation and their use in pharmaceutical compositions
|
DE10238470A1
(de)
|
2002-08-22 |
2004-03-04 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
|
DE10238477A1
(de)
|
2002-08-22 |
2004-03-04 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue Purinderivate, deren Herstellung und deren Verwendung als Arzneimittel
|
US7569574B2
(en)
|
2002-08-22 |
2009-08-04 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Purine derivatives, the preparation thereof and their use as pharmaceutical compositions
|
DE10238723A1
(de)
|
2002-08-23 |
2004-03-11 |
Bayer Ag |
Phenyl-substituierte Pyrazolyprimidine
|
DE10238724A1
(de)
|
2002-08-23 |
2004-03-04 |
Bayer Ag |
Alkyl-substituierte Pyrazolpyrimidine
|
AU2003262059A1
(en)
|
2002-09-11 |
2004-04-30 |
Takeda Pharmaceutical Company Limited |
Sustained release preparation
|
MXPA05002899A
(es)
|
2002-09-16 |
2005-05-27 |
Wyeth Corp |
Formulaciones de liberacion controlada para administracion oral de un agente terapeutico polipeptido y sus metodos de uso.
|
KR100867485B1
(ko)
|
2002-09-26 |
2008-11-10 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
병용 의약
|
WO2004033455A2
(en)
|
2002-10-08 |
2004-04-22 |
Novo Nordisk A/S |
Hemisuccinate salts of heterocyclic dpp-iv inhibitors
|
US20040122048A1
(en)
|
2002-10-11 |
2004-06-24 |
Wyeth Holdings Corporation |
Stabilized pharmaceutical composition containing basic excipients
|
US6861526B2
(en)
|
2002-10-16 |
2005-03-01 |
Pfizer Inc. |
Process for the preparation of (S,S)-cis-2-benzhydryl-3-benzylaminoquinuclidine
|
ATE390416T1
(de)
|
2002-10-18 |
2008-04-15 |
Merck & Co Inc |
Heterozyklische beta-aminoverbindungen als inhibitoren des dipeptidylpeptidase zur behandlung bzw. prevention von diabetes
|
JP2004161749A
(ja)
|
2002-10-24 |
2004-06-10 |
Toray Fine Chemicals Co Ltd |
光学活性含窒素化合物の製造方法
|
WO2004048379A1
(ja)
|
2002-11-01 |
2004-06-10 |
Sumitomo Pharmaceuticals Co., Ltd. |
キサンチン化合物
|
BR0315796A
(pt)
|
2002-11-07 |
2005-09-13 |
Merck & Co Inc |
Composto, composição farmacêutica, e, métodos para tratar diabetes, para tratar hiperglicemia, e para tratar obesidade em um mamìfero
|
DE10251927A1
(de)
|
2002-11-08 |
2004-05-19 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
|
US7482337B2
(en)
|
2002-11-08 |
2009-01-27 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
|
EP1564210B9
(en)
|
2002-11-20 |
2010-03-31 |
Japan Tobacco Inc. |
4-oxoquinoline compounds and utilization thereof as hiv integrase inhibitors
|
JP3567162B1
(ja)
|
2002-11-20 |
2004-09-22 |
日本たばこ産業株式会社 |
4−オキソキノリン化合物及びそのhivインテグラーゼ阻害剤としての利用
|
DE10254304A1
(de)
|
2002-11-21 |
2004-06-03 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
|
US7109192B2
(en)
|
2002-12-03 |
2006-09-19 |
Boehringer Ingelheim Pharma Gmbh & Co Kg |
Substituted imidazo-pyridinones and imidazo-pyridazinones, the preparation thereof and their use as pharmaceutical compositions
|
UY28103A1
(es)
|
2002-12-03 |
2004-06-30 |
Boehringer Ingelheim Pharma |
Nuevas imidazo-piridinonas sustituidas, su preparación y su empleo como medicacmentos
|
JP4651934B2
(ja)
|
2002-12-04 |
2011-03-16 |
キッセイ薬品工業株式会社 |
ベンジルフェノール誘導体、それを含有する医薬組成物およびその医薬用途
|
WO2004052362A1
(en)
|
2002-12-10 |
2004-06-24 |
Novartis Ag |
Combination of an dpp-iv inhibitor and a ppar-alpha compound
|
DE10258008B4
(de)
|
2002-12-12 |
2006-02-02 |
Sanofi-Aventis Deutschland Gmbh |
Heterocyclische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
|
DE10258007B4
(de)
|
2002-12-12 |
2006-02-09 |
Sanofi-Aventis Deutschland Gmbh |
Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
|
DE10351663A1
(de)
|
2002-12-20 |
2004-07-01 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Pulverförmige Arzneimittel enthaltend ein Tiotropiumsalz und Salmeterolxinafoat
|
US20040152720A1
(en)
|
2002-12-20 |
2004-08-05 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Powdered medicaments containing a tiotropium salt and salmeterol xinafoate
|
CN100391963C
(zh)
|
2003-01-03 |
2008-06-04 |
布里斯托尔-迈尔斯斯奎布公司 |
制备c-芳基葡糖苷sglt2抑制剂的方法
|
ATE424215T1
(de)
|
2003-01-08 |
2009-03-15 |
Novartis Vaccines & Diagnostic |
Stabilisierte wässrige zusammensetzungen mit gewebefaktorinhibitor (tfpi) oder gewebefaktorinhibitor-variante
|
ATE374766T1
(de)
|
2003-01-14 |
2007-10-15 |
Arena Pharm Inc |
1,2,3-trisubstituierte aryl- und heteroarylderivate als modulatoren des metabolismus zur vorbeugung und behandlung von metabolismus-bedingten krankheiten wie diabetes oder hyperglykämie
|
DE10335027A1
(de)
|
2003-07-31 |
2005-02-17 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verwendung von Angiotensin II Rezeptor Antagonisten
|
PE20040950A1
(es)
|
2003-02-14 |
2005-01-01 |
Theravance Inc |
DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
|
JP2004250336A
(ja)
|
2003-02-18 |
2004-09-09 |
Kao Corp |
コーティング錠及び糖衣錠の製造法
|
WO2004076470A2
(en)
|
2003-02-27 |
2004-09-10 |
Bristol-Myers Squibb Company |
A non-cryogenic process for forming glycosides
|
US7135575B2
(en)
|
2003-03-03 |
2006-11-14 |
Array Biopharma, Inc. |
P38 inhibitors and methods of use thereof
|
US7442387B2
(en)
|
2003-03-06 |
2008-10-28 |
Astellas Pharma Inc. |
Pharmaceutical composition for controlled release of active substances and manufacturing method thereof
|
MXPA05009564A
(es)
|
2003-03-12 |
2005-11-17 |
Univ Arizona |
Sales de bases debiles.
|
TWI309980B
(en)
|
2003-03-14 |
2009-05-21 |
Yamanouchi Pharma Co Ltd |
C-glycoside derivatives or salts thereof
|
WO2004082402A1
(en)
|
2003-03-18 |
2004-09-30 |
Novartis Ag |
Compositions comprising fatty acids and amino acids
|
US20040220186A1
(en)
|
2003-04-30 |
2004-11-04 |
Pfizer Inc. |
PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
|
JPWO2004096806A1
(ja)
|
2003-04-30 |
2006-07-13 |
大日本住友製薬株式会社 |
縮合イミダゾール誘導体
|
US7674486B2
(en)
|
2003-05-14 |
2010-03-09 |
Indus Biotech Pvt. Ltd. |
Synergistic composition for the treatment of diabetes mellitus
|
TW200510277A
(en)
|
2003-05-27 |
2005-03-16 |
Theravance Inc |
Crystalline form of β2-adrenergic receptor agonist
|
AU2004252075A1
(en)
|
2003-06-03 |
2005-01-06 |
The Regents Of The University Of California |
Compositions and methods for treatment of disease with acetylated disaccharides
|
AU2003902828A0
(en)
|
2003-06-05 |
2003-06-26 |
Fujisawa Pharmaceutical Co., Ltd. |
Dpp-iv inhibitor
|
JP2004359630A
(ja)
|
2003-06-06 |
2004-12-24 |
Yamanouchi Pharmaceut Co Ltd |
ジフルオロジフェニルメタン誘導体及びその塩
|
DE10327439A1
(de)
|
2003-06-18 |
2005-01-05 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue Imidazopyridazinon- und Imidazopyridonderivate, deren Herstellung und deren Verwendung als Arzneimittel
|
US7566707B2
(en)
|
2003-06-18 |
2009-07-28 |
Boehringer Ingelheim International Gmbh |
Imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions
|
AU2004251830B8
(en)
|
2003-06-20 |
2009-11-26 |
F. Hoffmann-La Roche Ag |
Pyrido[2, 1-A]-isoquinoline derivatives as DPP-IV inhibitors
|
ES2327740T3
(es)
|
2003-06-20 |
2009-11-03 |
F. Hoffmann-La Roche Ag |
Hexahidropiridoisoquinolinas como inhibidoras de la dpp-iv.
|
JO2625B1
(en)
|
2003-06-24 |
2011-11-01 |
ميرك شارب اند دوم كوربوريشن |
Phosphoric acid salts of dipeptidyl betidase inhibitor 4
|
AR045047A1
(es)
|
2003-07-11 |
2005-10-12 |
Arena Pharm Inc |
Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
|
AU2004257267B2
(en)
|
2003-07-14 |
2009-12-03 |
Arena Pharmaceuticals,Inc |
Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
|
PT1558220E
(pt)
|
2003-07-24 |
2010-03-12 |
Rasendrakumar Jha |
Composições orais para tratamento da diabetes
|
EP1679965A4
(en)
|
2003-08-01 |
2009-05-27 |
Janssen Pharmaceutica Nv |
SUBSTITUTED FUSED HETEROCYCLIC C-GLYCOSIDES
|
KR20060054410A
(ko)
|
2003-08-01 |
2006-05-22 |
제네랩스 테크놀로지스, 인코포레이티드 |
플라비비리다에에 대한 2고리 이미다졸 유도체
|
CN103819465A
(zh)
|
2003-08-01 |
2014-05-28 |
田边三菱制药株式会社 |
新颖化合物
|
US6995183B2
(en)
|
2003-08-01 |
2006-02-07 |
Bristol Myers Squibb Company |
Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
|
JP4131216B2
(ja)
|
2003-08-20 |
2008-08-13 |
Jsr株式会社 |
ポリアリーレンおよびその製造方法、ならびに高分子固体電解質およびプロトン伝導膜
|
US7375090B2
(en)
|
2003-08-26 |
2008-05-20 |
Boehringer Ingelheim International Gmbh |
Glucopyranosyloxy-pyrazoles, pharmaceutical compositions containing these compounds, the use thereof and processed for the preparation thereof
|
DE502004008951D1
(de)
|
2003-08-26 |
2009-03-19 |
Boehringer Ingelheim Pharma |
Glucopyranosyloxy-pyrazole, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
|
US20070190022A1
(en)
|
2003-08-29 |
2007-08-16 |
Bacopoulos Nicholas G |
Combination methods of treating cancer
|
EP1699777B1
(en)
|
2003-09-08 |
2012-12-12 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
EP1671649B1
(en)
|
2003-10-03 |
2011-11-23 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase IV inhibitors for treating diabetic patients with sulfonylurea secondary failure
|
US20050085680A1
(en)
|
2003-10-21 |
2005-04-21 |
Joseph Auerbach |
Method for industrial decontamination
|
KR20120008093A
(ko)
|
2003-11-17 |
2012-01-25 |
노파르티스 아게 |
디펩티딜 펩티다제 ⅳ 억제제의 용도
|
DE10355304A1
(de)
|
2003-11-27 |
2005-06-23 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue 8-(Piperazin-1-yl)-und 8-([1,4]Diazepan-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
|
US20070219178A1
(en)
|
2003-12-04 |
2007-09-20 |
Eisai Co., Ltd. |
Preventive or therapeutic agents for multiple sclerosis
|
US7217711B2
(en)
|
2003-12-17 |
2007-05-15 |
Boehringer Ingelheim International Gmbh |
Piperazin-1-yl and 2-([1,4]diazepan-1-yl)-imidazo[4,5-d]-pyridazin-4-ones, the preparation thereof and their use as pharmaceutical compositions
|
DE10359098A1
(de)
|
2003-12-17 |
2005-07-28 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue 2-(Piperazin-1-yl)- und 2-([1,4]Diazepan-1-yl)-imidazo[4,5-d]pyridazin-4-one, deren Herstellung und deren Verwendung als Arzneimittel
|
US7355051B2
(en)
|
2003-12-18 |
2008-04-08 |
Tibotec Pharmaceuticals |
Piperdine-amino-benzimidazole derivatives as inhibitors of respiratory syncytial virus replication
|
US7371732B2
(en)
|
2003-12-22 |
2008-05-13 |
Boehringer Ingelheim International Gmbh |
Glucopyranosyloxy-substituted aromatic compounds, medicaments containing such compounds, their use and process for their manufacture
|
DE10361133A1
(de)
|
2003-12-22 |
2005-07-21 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Glucopyranosyloxy-substituierte Aromaten, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
DE10360835A1
(de)
|
2003-12-23 |
2005-07-21 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Bicyclische Imidazolverbindungen, deren Herstellung und deren Verwendung als Arzneimittel
|
NZ547965A
(en)
|
2003-12-24 |
2009-12-24 |
Prosidion Ltd |
1,2,4-Oxadiazole derivatives as GPCR receptor agonists
|
US7501426B2
(en)
|
2004-02-18 |
2009-03-10 |
Boehringer Ingelheim International Gmbh |
8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
|
AU2005219508B2
(en)
|
2004-02-18 |
2012-02-16 |
Boehringer Ingelheim International Gmbh |
8-[3-amino-piperidin-1-yl]-xanthine, the production thereof and the use in the form of a DPP inhibitor
|
DE102004019540A1
(de)
|
2004-04-22 |
2005-11-10 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue Arzneimittelkombinationen zur Behandlung von Atemwegserkrankungen
|
DE102004009039A1
(de)
|
2004-02-23 |
2005-09-08 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und Verwendung als Arzneimittel
|
JP5078350B2
(ja)
|
2004-03-04 |
2012-11-21 |
キッセイ薬品工業株式会社 |
縮合ヘテロ環誘導体、それを含有する医薬組成物およびその医薬用途
|
WO2005085237A1
(ja)
|
2004-03-04 |
2005-09-15 |
Kissei Pharmaceutical Co., Ltd. |
縮合複素環誘導体、それを含有する医薬組成物およびその医薬用途
|
EP1593671A1
(en)
|
2004-03-05 |
2005-11-09 |
Graffinity Pharmaceuticals AG |
DPP-IV inhibitors
|
US7393847B2
(en)
|
2004-03-13 |
2008-07-01 |
Boehringer Ingleheim International Gmbh |
Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions
|
GEP20094679B
(en)
|
2004-03-15 |
2009-05-10 |
Takeda Pharmaceuticals Co |
Dipeptidyl peptidase inhibitors
|
BRPI0508830B8
(pt)
|
2004-03-16 |
2021-05-25 |
Boehringer Ingelheim Int |
derivados de benzeno substituídos por glucopiranosila, medicamentos contendo esses compostos, seu uso e processo para sua fabricação
|
EP1577306A1
(de)
|
2004-03-17 |
2005-09-21 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
Neue Benzoxazinonderivate als langwirksame Betamimetika zur Behandlung von Atemwegserkrankungen
|
WO2005097798A1
(de)
|
2004-04-10 |
2005-10-20 |
Boehringer Ingelheim International Gmbh |
Neue 2-amino-imidazo[4,5-d]pyridazin-4-one und 2-amino-imidazo[4,5-c]pyridin-4-one, deren herstellung und deren verwendung als arzneimittel
|
US7179809B2
(en)
|
2004-04-10 |
2007-02-20 |
Boehringer Ingelheim International Gmbh |
2-Amino-imidazo[4,5-d]pyridazin-4-ones, their preparation and their use as pharmaceutical compositions
|
US20050239778A1
(en)
|
2004-04-22 |
2005-10-27 |
Boehringer Ingelheim International Gmbh |
Novel medicament combinations for the treatment of respiratory diseases
|
US20050244502A1
(en)
|
2004-04-28 |
2005-11-03 |
Mathias Neil R |
Composition for enhancing absorption of a drug and method
|
US7439370B2
(en)
|
2004-05-10 |
2008-10-21 |
Boehringer Ingelheim International Gmbh |
Imidazole derivatives, their preparation and their use as intermediates for the preparation of pharmaceutical compositions and pesticides
|
PL1753748T3
(pl)
|
2004-05-12 |
2010-01-29 |
Pfizer Prod Inc |
Pochodne proliny i ich zastosowanie jako inhibitorów peptydazy dipeptylowej IV
|
DE102004024454A1
(de)
|
2004-05-14 |
2005-12-08 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue Enantiomerenreine Betaagonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
|
PE20060315A1
(es)
|
2004-05-24 |
2006-05-15 |
Irm Llc |
Compuestos de tiazol como moduladores de ppar
|
TWI354569B
(en)
|
2004-05-28 |
2011-12-21 |
Bristol Myers Squibb Co |
Coated tablet formulation and method
|
CA2567309A1
(en)
|
2004-06-01 |
2005-12-15 |
Ares Trading S.A. |
Method of stabilizing proteins
|
WO2005117861A1
(en)
|
2004-06-04 |
2005-12-15 |
Novartis Ag |
Use of organic compounds
|
EP1753459A2
(en)
|
2004-06-09 |
2007-02-21 |
Yasoo Health |
Composition and method for improving pancreatic islet cell survival
|
DE102004030502A1
(de)
|
2004-06-24 |
2006-01-12 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel
|
US7393836B2
(en)
|
2004-07-06 |
2008-07-01 |
Boehringer Ingelheim International Gmbh |
D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
|
JPWO2006006496A1
(ja)
|
2004-07-08 |
2008-04-24 |
アステラス製薬株式会社 |
アズレン誘導体の製造方法及びその合成中間体
|
RU2007105346A
(ru)
|
2004-07-14 |
2008-09-27 |
Новартис АГ (CH) |
Комбинация ингибиторов dpp-iv и соединений, модулирующих 5-нт3-и/или 5-нт4-рецепторы
|
DE102004034690A1
(de)
|
2004-07-17 |
2006-02-02 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Methyliden-D-xylopyranosyl-und Oxo-D-xylopyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
TW200606129A
(en)
|
2004-07-26 |
2006-02-16 |
Chugai Pharmaceutical Co Ltd |
Novel cyclohexane derivative, its prodrug, its salt and diabetic therapeutic agent containing the same
|
JP2008508213A
(ja)
|
2004-07-27 |
2008-03-21 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
D−グルコピラノシル−フェニル置換環状体、そのような化合物を含有する医薬品、それらの使用及びその製造方法
|
JP2006045156A
(ja)
|
2004-08-06 |
2006-02-16 |
Sumitomo Pharmaceut Co Ltd |
縮合ピラゾール誘導体
|
WO2006018150A1
(de)
|
2004-08-11 |
2006-02-23 |
Boehringer Ingelheim International Gmbh |
D-xylopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
|
TW200613275A
(en)
|
2004-08-24 |
2006-05-01 |
Recordati Ireland Ltd |
Lercanidipine salts
|
WO2006022428A1
(ja)
|
2004-08-26 |
2006-03-02 |
Takeda Pharmaceutical Company Limited |
糖尿病治療剤
|
DE102004043944A1
(de)
|
2004-09-11 |
2006-03-30 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue 8-(3-Amino-piperidin-1-yl)-7-(but-2-inyl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
|
DE102004044221A1
(de)
|
2004-09-14 |
2006-03-16 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue 3-Methyl-7-butinyl-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
|
CN1759834B
(zh)
|
2004-09-17 |
2010-06-23 |
中国医学科学院医药生物技术研究所 |
黄连素或其与辛伐他汀联合在制备用于预防或治疗与血脂有关疾病或症状的产品中用途
|
EP1799637A1
(en)
|
2004-09-23 |
2007-06-27 |
Amgen, Inc |
Substituted sulfonamidopropionamides and methods of use
|
AR051446A1
(es)
|
2004-09-23 |
2007-01-17 |
Bristol Myers Squibb Co |
Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
|
DE102004048388A1
(de)
|
2004-10-01 |
2006-04-06 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
D-Pyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
JP2008515905A
(ja)
|
2004-10-08 |
2008-05-15 |
ノバルティス アクチエンゲゼルシャフト |
有機化合物の組合せ剤
|
AP2007003973A0
(en)
|
2004-10-12 |
2007-07-30 |
Glenmark Pharmaceuticals Sa |
Novel dideptidyl peptidase IV inhibitors, pharmaceutical compositions containing them, and proces for their preparation
|
CA2581298A1
(en)
|
2004-10-25 |
2006-05-04 |
Novartis Ag |
Combination of dpp-iv inhibitor, ppar antidiabetic and metformin
|
DE102004054054A1
(de)
|
2004-11-05 |
2006-05-11 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
|
DE102005013967A1
(de)
|
2004-11-05 |
2006-10-05 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue Bradykinin-B1-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
|
ES2314743T3
(es)
|
2004-12-16 |
2009-03-16 |
Boehringer Ingelheim International Gmbh |
Derivados de benceno sustituidos con glucopiranosilo, medicamentos que contienen a este tipo de compuestos, su uso y procedimiento para su fabricacion.
|
DE102004063099B4
(de)
|
2004-12-22 |
2009-02-12 |
Sanofi-Aventis Deutschland Gmbh |
Verfahren zur Herstellung von Thiophenglycosidderivaten
|
CA2590912A1
(en)
|
2004-12-24 |
2006-06-29 |
Dainippon Sumitomo Pharma Co., Ltd. |
Bicyclic pyrrole derivatives
|
KR100760430B1
(ko)
|
2004-12-31 |
2007-10-04 |
한미약품 주식회사 |
당뇨병 치료제의 경구 투여용 서방성 복합 제제 및 이의제조 방법
|
MY148521A
(en)
|
2005-01-10 |
2013-04-30 |
Arena Pharm Inc |
Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
|
DOP2006000008A
(es)
|
2005-01-10 |
2006-08-31 |
Arena Pharm Inc |
Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
|
GT200600008A
(es)
|
2005-01-18 |
2006-08-09 |
|
Formulacion de compresion directa y proceso
|
TW200637869A
(en)
|
2005-01-28 |
2006-11-01 |
Chugai Pharmaceutical Co Ltd |
The spiroketal derivatives and the use as therapeutical agent for diabetes of the same
|
DE602006009772D1
(de)
|
2005-02-23 |
2009-11-26 |
Boehringer Ingelheim Int |
Glucopyranosylsubstituierte ((hetero)arylethynyl-benzyl)-benzenderivative und deren verwendung als inhibitoren des natriumabhängigen glucose-cotransporters typ 2 (sglt2)
|
EP1874787B1
(en)
|
2005-04-15 |
2009-12-30 |
Boehringer Ingelheim International GmbH |
Glucopyranosyl-substituted (heteroaryloxy-benzyl)-benzene derivatives as sglt inhibitors
|
CN101277949A
(zh)
|
2005-04-22 |
2008-10-01 |
阿兰托斯制药控股公司 |
二肽基肽酶-ⅳ抑制剂
|
CN100539942C
(zh)
|
2005-04-25 |
2009-09-16 |
株式会社日立制作所 |
利用磁共振的检查装置及核磁共振信号接收用线圈
|
US7723309B2
(en)
|
2005-05-03 |
2010-05-25 |
Boehringer Ingelheim International Gmbh |
Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
|
UA91546C2
(uk)
|
2005-05-03 |
2010-08-10 |
Бьорінгер Інгельхайм Інтернаціональ Гмбх |
КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
|
US7772191B2
(en)
|
2005-05-10 |
2010-08-10 |
Boehringer Ingelheim International Gmbh |
Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
|
CN101203494A
(zh)
|
2005-05-25 |
2008-06-18 |
惠氏公司 |
合成经取代3-氰基喹啉和其中间物的方法
|
GT200600218A
(es)
|
2005-06-10 |
2007-03-28 |
|
Formulación y proceso de compresión directa
|
EA016397B1
(ru)
|
2005-06-20 |
2012-04-30 |
Декоуд Дженетикс Ехф. |
Генетические варианты гена tcf7l2 как диагностические маркеры риска возникновения сахарного диабета ii типа
|
WO2007000445A1
(en)
|
2005-06-29 |
2007-01-04 |
Boehringer Ingelheim International Gmbh |
Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
|
ATE483732T1
(de)
|
2005-07-08 |
2010-10-15 |
Pfizer Ltd |
Madcam-antikörper
|
TW200733966A
(en)
|
2005-07-27 |
2007-09-16 |
Boehringer Ingelheim Int |
Glucopyranosyl-substituted ((hetero)cycloalkylethynyl-benzyl)-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
|
UY29694A1
(es)
|
2005-07-28 |
2007-02-28 |
Boehringer Ingelheim Int |
Metodos para prevenir y tratar trastornos metabolicos y nuevos derivados de pirazol-o-glucosido
|
DE102005035891A1
(de)
|
2005-07-30 |
2007-02-08 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
|
CN101232873A
(zh)
|
2005-08-11 |
2008-07-30 |
霍夫曼-拉罗奇有限公司 |
含有dpp-iv抑制剂的药物组合物
|
ATE484499T1
(de)
|
2005-08-30 |
2010-10-15 |
Boehringer Ingelheim Int |
Glucopyranosyl-substituierte benzyl-derivate, medikamente mit solchen verbindungen, ihre verwendung und herstellungsverfahren dafür
|
EP1760076A1
(en)
|
2005-09-02 |
2007-03-07 |
Ferring B.V. |
FAP Inhibitors
|
AU2006289093A1
(en)
|
2005-09-08 |
2007-03-15 |
Boehringer Ingelheim International Gmbh |
Crystalline forms of 1-chloro-4-(beta-D-glucopyranos-1-yl)-2-(4-ethynyl-benzyl)-benzene, methods for its preparation and the use thereof for preparing medicaments
|
MY147393A
(en)
|
2005-09-14 |
2012-11-30 |
Takeda Pharmaceutical |
Administration of dipeptidyl peptidase inhibitors
|
AR056195A1
(es)
|
2005-09-15 |
2007-09-26 |
Boehringer Ingelheim Int |
Procedimientos para preparar derivados de (etinil-bencil)-benceno sustituidos de glucopiranosilo y compuestos intermedios de los mismos
|
CA2619093A1
(en)
|
2005-09-16 |
2007-03-29 |
Arena Pharmaceuticals, Inc. |
Modulators of metabolism and the treatment of disorders related thereto
|
JP5072848B2
(ja)
|
2005-09-20 |
2012-11-14 |
ノバルティス アーゲー |
低血糖イベントを低減するためのdpp−iv阻害剤の使用
|
JOP20180109A1
(ar)
|
2005-09-29 |
2019-01-30 |
Novartis Ag |
تركيبة جديدة
|
JP2009510007A
(ja)
|
2005-09-30 |
2009-03-12 |
ベーリンガー インゲルハイム フェトメディカ ゲゼルシャフト ミット ベシュレンクテル ハフツング |
メロキシカムを含む医薬調製
|
JP2009513633A
(ja)
|
2005-10-25 |
2009-04-02 |
メルク エンド カムパニー インコーポレーテッド |
糖尿病および高血圧を治療するためのジペプチジルペプチダーゼ−4インヒビターと降圧薬との組合せ
|
CN101300298A
(zh)
|
2005-11-04 |
2008-11-05 |
Ls电线有限公司 |
Mdh-聚合物混合粒子的合成
|
WO2007078726A2
(en)
|
2005-12-16 |
2007-07-12 |
Merck & Co., Inc. |
Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin
|
GB0526291D0
(en)
|
2005-12-23 |
2006-02-01 |
Prosidion Ltd |
Therapeutic method
|
EP1966215A1
(en)
|
2005-12-23 |
2008-09-10 |
Novartis AG |
Condensed heterocyclic compounds useful as dpp-iv inhibitors
|
CA2635399A1
(en)
|
2006-01-06 |
2007-10-25 |
Novartis Ag |
Use.of vildagliptin for the treatment of diabetes
|
JP2009531291A
(ja)
|
2006-02-15 |
2009-09-03 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
グルコピラノシル置換ベンゾニトリル誘導体、それらの化合物を含有する医薬組成物、それらの使用及び製造方法
|
WO2007099345A1
(en)
|
2006-03-02 |
2007-09-07 |
Betagenon Ab |
Medical use of bmp-2 and/ or bmp-4
|
US8784886B2
(en)
*
|
2006-03-09 |
2014-07-22 |
GlaxoSmithKline, LLC |
Coating capsules with active pharmaceutical ingredients
|
US20070264370A1
(en)
*
|
2006-03-31 |
2007-11-15 |
Jeffers Michael G |
Composition and methods for the treatment of joint pain using Angelica gigas Nakai extract and powder as combined with Glucosamine Sulfate, or Chondroitin Sulfate and HCL, or MSM, or aspirin, or Celedrin, and as combinations thereof in powder, pill, capsule, spray, liquid, and gelcap form
|
PE20071221A1
(es)
|
2006-04-11 |
2007-12-14 |
Arena Pharm Inc |
Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
|
US8455435B2
(en)
|
2006-04-19 |
2013-06-04 |
Ludwig-Maximilians-Universitat Munchen |
Remedies for ischemia
|
PE20080697A1
(es)
|
2006-05-03 |
2008-08-05 |
Boehringer Ingelheim Int |
Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
|
EP1852108A1
(en)
|
2006-05-04 |
2007-11-07 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
DPP IV inhibitor formulations
|
PE20110235A1
(es)
|
2006-05-04 |
2011-04-14 |
Boehringer Ingelheim Int |
Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
|
CA2810839A1
(en)
|
2006-05-04 |
2007-11-15 |
Boehringer Ingelheim International Gmbh |
A polymorphic form of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(r)-amino-piperidin-1-yl)-xanthine
|
KR101424832B1
(ko)
|
2006-05-16 |
2014-08-06 |
길리애드 사이언시즈, 인코포레이티드 |
악성 혈액 종양 치료 방법 및 악성 혈액 종양 치료용 조성물
|
KR20070111099A
(ko)
|
2006-05-16 |
2007-11-21 |
영진약품공업주식회사 |
시타글립틴 염산염의 신규 결정형, 이의 제조 방법과 이를포함하는 약학적 조성물
|
US20080064717A1
(en)
|
2006-05-19 |
2008-03-13 |
Rajesh Iyengar |
Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme
|
KR100858848B1
(ko)
*
|
2006-05-23 |
2008-09-17 |
한올제약주식회사 |
메트포르민 서방정
|
DE602007012692D1
(de)
|
2006-06-16 |
2011-04-07 |
Lek Pharmaceuticals |
Pharmazeutische zusammensetzung mit hydrochlorothiazid und telmisartan
|
WO2007149797A2
(en)
|
2006-06-19 |
2007-12-27 |
Novartis Ag |
Use of organic compounds
|
WO2007148185A2
(en)
|
2006-06-21 |
2007-12-27 |
Pfizer Products Inc. |
Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors
|
AT503443B1
(de)
|
2006-06-23 |
2007-10-15 |
Leopold Franzens Uni Innsbruck |
Verfahren zur herstellung einer eisfläche für eissportbahnen
|
TW200811140A
(en)
|
2006-07-06 |
2008-03-01 |
Arena Pharm Inc |
Modulators of metabolism and the treatment of disorders related thereto
|
TW200811147A
(en)
|
2006-07-06 |
2008-03-01 |
Arena Pharm Inc |
Modulators of metabolism and the treatment of disorders related thereto
|
JP2010500326A
(ja)
|
2006-08-08 |
2010-01-07 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
糖尿病の治療のためのdpp−iv阻害剤としてのピロロ[3,2−d]ピリミジン
|
US8039441B2
(en)
*
|
2006-08-15 |
2011-10-18 |
Boehringer Ingelheim International Gmbh |
Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as SGLT inhibitors and process for their manufacture
|
NZ574664A
(en)
|
2006-08-17 |
2012-06-29 |
Wellstat Therapeutics Corp |
Combination treatment for metabolic disorders comprising an incretin mimetic such as exendin or a dppv iv inhibitor
|
US20080221174A1
(en)
*
|
2006-08-30 |
2008-09-11 |
Jagotec Ag |
Controlled release nisoldipine compositions
|
DE102006042586B4
(de)
|
2006-09-11 |
2014-01-16 |
Betanie B.V. International Trading |
Verfahren zum mikropartikulären Beladen von hochpolymeren Kohlenhydraten mit hydrophoben Wirkflüssigkeiten
|
EP2074130A1
(en)
|
2006-09-21 |
2009-07-01 |
Boehringer Ingelheim International GmbH |
Glucopyranosyl-substituted difluorobenzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
|
JP2010507629A
(ja)
|
2006-10-27 |
2010-03-11 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
4−(β−D−グルコピラノス−1−イル)−1−メチル−2−[4−((S)−テトラヒドロフラン−3−イルオキシ)−ベンジル]−ベンゼンの結晶形、その製造方法及び医薬品を製造するための使用
|
US7956201B2
(en)
|
2006-11-06 |
2011-06-07 |
Hoffman-La Roche Inc. |
Process for the preparation of (S)-4-fluoromethyl-dihydro-furan-2-one
|
CL2007003187A1
(es)
|
2006-11-06 |
2008-03-07 |
Boehringer Ingelheim Int |
Compuestos derivados de bencil-benzonitrilo sustituido con glucopiranosilo y sus sales; procedimiento de preparacion; compuestos intermediarios; proceso para preparar los compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de
|
CA2669043A1
(en)
|
2006-11-09 |
2008-05-15 |
Boehringer Ingelheim International Gmbh |
Combination therapy with sglt-2 inhibitors and their pharmaceutical compositions
|
WO2008062273A2
(en)
|
2006-11-20 |
2008-05-29 |
Cadila Pharmaceuticals Limited |
Solid oral dosage form having antidiabetic drug combination
|
WO2008070692A2
(en)
|
2006-12-06 |
2008-06-12 |
Smithkline Beecham Corporation |
Bicyclic compounds and use as antidiabetics
|
US7638541B2
(en)
|
2006-12-28 |
2009-12-29 |
Metabolex Inc. |
5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
|
AR064736A1
(es)
|
2007-01-04 |
2009-04-22 |
Prosidion Ltd |
Agonistas de gpcr
|
CL2008000133A1
(es)
|
2007-01-19 |
2008-05-23 |
Boehringer Ingelheim Int |
Composicion farmaceutica que comprende un compuesto derivado de pirazol-o-glucosido combinado con al menos un segundo agente terapeutico; y uso de la composicion para el tratamiento de diabetes mellitus, cataratas, neuropatia, infarto de miocardio, e
|
JP2010516721A
(ja)
|
2007-01-26 |
2010-05-20 |
サノフィ−アベンティス |
フェノチアジン誘導体、その製造方法及び医薬としてその使用
|
EP2382972A1
(en)
|
2007-01-26 |
2011-11-02 |
Boehringer Ingelheim International GmbH |
Methods for preventing and treating neurodegenerative disorders
|
JP5284968B2
(ja)
|
2007-02-01 |
2013-09-11 |
武田薬品工業株式会社 |
アログリプチンおよびピオグリタゾンを含有する固形製剤
|
WO2008093878A1
(en)
|
2007-02-01 |
2008-08-07 |
Takeda Pharmaceutical Company Limited |
Tablet preparation without causing a tableting trouble
|
ITFI20070042A1
(it)
|
2007-02-21 |
2008-08-22 |
Laboratori Guidotti Spa |
Formulazione farmaceutica e compressa comprendente detta formulazione.
|
WO2008101938A1
(en)
|
2007-02-21 |
2008-08-28 |
Boehringer Ingelheim International Gmbh |
Glucopyranosyl-substituted benzyl-benzonitrile derivatives, medicaments containing such compounds, their use and process for their manufacture
|
JP2010519273A
(ja)
|
2007-02-21 |
2010-06-03 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
四置換グルコピラノシル化ベンゼン誘導体、このような化合物を含む薬物、それらの使用及びそれらの製造方法
|
JP2010521492A
(ja)
|
2007-03-15 |
2010-06-24 |
ネクティド,インク. |
徐放性ビグアニド組成物、および即時性ジペプチジルペプチダーゼiv阻害剤組成物を含む抗糖尿病合剤
|
PE20090185A1
(es)
|
2007-03-22 |
2009-02-28 |
Bristol Myers Squibb Co |
Formulaciones farmaceuticas que contienen un inhibidor sglt2
|
TW200904454A
(en)
|
2007-03-22 |
2009-02-01 |
Bristol Myers Squibb Co |
Methods for treating obesity employing an SGLT2 inhibitor and compositions thereof
|
AU2008233548B2
(en)
|
2007-04-03 |
2011-12-01 |
Mitsubishi Tanabe Pharma Corporation |
Combined use of dipeptidyl peptidase IV inhibitor compound and sweetener
|
US9050123B2
(en)
|
2007-04-16 |
2015-06-09 |
Smith & Nephew, Inc. |
Powered surgical system
|
PE20090696A1
(es)
|
2007-04-20 |
2009-06-20 |
Bristol Myers Squibb Co |
Formas cristalinas de saxagliptina y procesos para preparar las mismas
|
EP2144902B1
(en)
|
2007-05-04 |
2012-05-16 |
Bristol-Myers Squibb Company |
[6,6]and [6,7]-bicyclic gpr119 g protein-coupled receptor agonists
|
JP2010528023A
(ja)
|
2007-05-18 |
2010-08-19 |
ブリストル−マイヤーズ スクイブ カンパニー |
Sglt2阻害剤の結晶構造およびその製造方法
|
EP2178493B2
(en)
|
2007-07-09 |
2015-12-09 |
Symrise AG |
Stable soluble salts of phenylbenzimidazole sulfonic acid at pH 6.0 to below 6.8
|
GEP20125672B
(en)
|
2007-07-19 |
2012-10-25 |
Takeda Pharmaceuticals Co |
) solid composition containing alogliptin and metformin hydrochloride
|
PE20090603A1
(es)
|
2007-08-16 |
2009-06-11 |
Boehringer Ingelheim Int |
Composicion farmaceutica que comprende un inhibidor de sglt2 y un inhibidor de dpp iv
|
UY31290A1
(es)
|
2007-08-16 |
2009-03-31 |
|
Composicion farmacéutica que comprende un derivado de pirazol-o-glucosido
|
FR2920023B1
(fr)
|
2007-08-16 |
2013-02-08 |
Sanofi Aventis |
Derives de l'indol-2-one disubstitues en 3, leur preparation et leur application en therapeutique
|
CL2008002427A1
(es)
|
2007-08-16 |
2009-09-11 |
Boehringer Ingelheim Int |
Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2.
|
PE20090597A1
(es)
|
2007-08-16 |
2009-06-06 |
Boehringer Ingelheim Int |
Composicion farmaceutica que comprende un derivado de pirazol-o-glucosido
|
CN101784278A
(zh)
|
2007-08-17 |
2010-07-21 |
贝林格尔.英格海姆国际有限公司 |
用于治疗fab-相关的疾病的嘌呤衍生物
|
PT2200606T
(pt)
|
2007-09-10 |
2017-12-13 |
Janssen Pharmaceutica Nv |
Processo para a preparação de compostos úteis como inibidores de sglt
|
PL2209800T3
(pl)
|
2007-11-16 |
2013-12-31 |
Novo Nordisk As |
Stabilne kompozycje farmaceutyczne zawierające liraglutyd i degludec
|
CN101234105A
(zh)
|
2008-01-09 |
2008-08-06 |
北京润德康医药技术有限公司 |
一种含有二甲双胍和维格列汀的药用组合物及其制备方法
|
US20090186086A1
(en)
|
2008-01-17 |
2009-07-23 |
Par Pharmaceutical, Inc. |
Solid multilayer oral dosage forms
|
CL2008003653A1
(es)
|
2008-01-17 |
2010-03-05 |
Mitsubishi Tanabe Pharma Corp |
Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
|
TW200936136A
(en)
|
2008-01-28 |
2009-09-01 |
Sanofi Aventis |
Tetrahydroquinoxaline urea derivatives, their preparation and their therapeutic application
|
WO2009099734A1
(en)
|
2008-02-05 |
2009-08-13 |
Merck & Co., Inc. |
Pharmaceutical compositions of a combination of metformin and a dipeptidyl peptidase-iv inhibitor
|
US20090226517A1
(en)
*
|
2008-02-06 |
2009-09-10 |
Vinita Umashankar Vyas |
Pharmaceutical formulations comprising duloxetine
|
EP2259676A4
(en)
*
|
2008-03-04 |
2011-03-16 |
Merck Sharp & Dohme |
PHARMACEUTICAL COMPOSITIONS OF A COMBINATION OF METFORMIN AND A DIPEPTIDYL PEPTIDASE-IV INHIBITOR
|
GEP20135844B
(en)
|
2008-03-05 |
2013-06-10 |
Takeda Pharmaceutical |
Heterocyclic compound
|
US8551524B2
(en)
|
2008-03-14 |
2013-10-08 |
Iycus, Llc |
Anti-diabetic combinations
|
MX2010010562A
(es)
|
2008-03-31 |
2010-12-07 |
Metabolex Inc |
Compuestos de oximetilen-arilo y uso de los mismos.
|
PE20140960A1
(es)
|
2008-04-03 |
2014-08-15 |
Boehringer Ingelheim Int |
Formulaciones que comprenden un inhibidor de dpp4
|
PE20100156A1
(es)
|
2008-06-03 |
2010-02-23 |
Boehringer Ingelheim Int |
Tratamiento de nafld
|
UY32030A
(es)
|
2008-08-06 |
2010-03-26 |
Boehringer Ingelheim Int |
"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
|
MX370599B
(es)
|
2008-08-15 |
2019-12-18 |
Boehringer Ingelheim Int |
Derivados de purina para su uso en el tratamiento de enfermedades relacionadas con fab.
|
JP2010053576A
(ja)
|
2008-08-27 |
2010-03-11 |
Sumitomo Forestry Co Ltd |
舗装用マット
|
US8513264B2
(en)
|
2008-09-10 |
2013-08-20 |
Boehringer Ingelheim International Gmbh |
Combination therapy for the treatment of diabetes and related conditions
|
UY32177A
(es)
|
2008-10-16 |
2010-05-31 |
Boehringer Ingelheim Int |
Tratamiento de diabetes en pacientes con control glucémico insuficiente a pesar de la terapia con fármaco, oral o no, antidiabético
|
WO2010045656A2
(en)
|
2008-10-17 |
2010-04-22 |
Nectid, Inc. |
Novel sglt2 inhibitor dosage forms
|
AU2009331471B2
(en)
|
2008-12-23 |
2015-09-03 |
Boehringer Ingelheim International Gmbh |
Salt forms of organic compound
|
TW201036975A
(en)
|
2009-01-07 |
2010-10-16 |
Boehringer Ingelheim Int |
Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
|
TWI466672B
(zh)
|
2009-01-29 |
2015-01-01 |
Boehringer Ingelheim Int |
小兒科病人糖尿病之治療
|
WO2010092163A2
(en)
|
2009-02-13 |
2010-08-19 |
Boehringer Ingelheim International Gmbh |
Antidiabetic medications
|
UY32427A
(es)
|
2009-02-13 |
2010-09-30 |
Boheringer Ingelheim Internat Gmbh |
Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma
|
JP5896276B2
(ja)
|
2009-02-13 |
2016-03-30 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
1型糖尿病、2型糖尿病、耐糖能障害又は高血糖の治療用sglt−2阻害薬
|
EP2395968B1
(en)
|
2009-02-13 |
2024-01-17 |
Boehringer Ingelheim International GmbH |
Pharmaceutical composition comprising glucopyranosyl diphenylmethane derivatives, pharmaceutical dosage form thereof, process for their preparation and uses thereof for improved glycemic control in a patient
|
SG173619A1
(en)
|
2009-02-13 |
2011-09-29 |
Boehringer Ingelheim Int |
Pharmaceutical composition comprising a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof
|
TW201031661A
(en)
|
2009-02-17 |
2010-09-01 |
Targacept Inc |
Fused benzazepines as neuronal nicotinic acetylcholine receptor ligands
|
EP2408780A2
(en)
|
2009-03-20 |
2012-01-25 |
Pfizer Inc. |
3-oxa-7-azabicycloý3.3.1¨nonanes
|
US8815292B2
(en)
|
2009-04-27 |
2014-08-26 |
Revalesio Corporation |
Compositions and methods for treating insulin resistance and diabetes mellitus
|
EP2435033A1
(en)
|
2009-05-27 |
2012-04-04 |
Bristol-Myers Squibb Company |
Methods for treating type 2 diabetes in patients resistant to previous treatment with other anti-diabetic drugs employing an sglt2 inhibitor and compositions thereof
|
WO2010140111A1
(en)
*
|
2009-06-02 |
2010-12-09 |
Ranbaxy Laboratories Limited |
Pharmaceutical compositions containing a combination of an antihistamine and a decongestant
|
EP2442806A1
(en)
|
2009-06-15 |
2012-04-25 |
Merck Sharp & Dohme Corp. |
Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with pioglitazone
|
MX2012000892A
(es)
|
2009-07-21 |
2012-06-01 |
Keryx Biopharmaceuticals Inc |
Formas de dosificacion de citrato ferrico.
|
HUE029381T2
(en)
|
2009-09-30 |
2017-02-28 |
Boehringer Ingelheim Int |
A method for preparing a crystalline form of 1-chloro-4- (beta-D-glucopyranos-1-yl) -2- [4 - ((S) -tetrahydrofuran-3-yloxy) benzyl] benzene.
|
BR112012007085B8
(pt)
|
2009-09-30 |
2021-05-25 |
Boehringer Ingelheim Int |
processos para a preparação de derivados de benzil-benzeno substituídos com glicopiranosila
|
US20120219623A1
(en)
|
2009-10-02 |
2012-08-30 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical compositions comprising bi-1356 and metformin
|
US10610489B2
(en)
|
2009-10-02 |
2020-04-07 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
|
WO2011060256A2
(en)
*
|
2009-11-13 |
2011-05-19 |
Bristol-Myers Squibb Company |
Bilayer tablet formulations
|
PL2498759T3
(pl)
|
2009-11-13 |
2019-03-29 |
Astrazeneca Ab |
Formulacje tabletek o natychmiastowym uwalnianiu
|
KR20240090632A
(ko)
|
2009-11-27 |
2024-06-21 |
베링거 인겔하임 인터내셔날 게엠베하 |
리나글립틴과 같은 dpp-iv 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
|
JP2010070576A
(ja)
|
2009-12-28 |
2010-04-02 |
Sato Pharmaceutical Co Ltd |
速溶解性錠剤
|
EP2547339A1
(en)
|
2010-03-18 |
2013-01-23 |
Boehringer Ingelheim International GmbH |
Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions
|
EP2368552A1
(en)
|
2010-03-25 |
2011-09-28 |
Boehringer Ingelheim Vetmedica GmbH |
1-[(3-cyano-pyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(r)-amino-piperidin-1-yl]-xanthine for the treatment of a metabolic disorder of a predominantly carnivorous non-human animal
|
JP2013523681A
(ja)
|
2010-03-30 |
2013-06-17 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Sglt2インヒビター及びppar−ガンマアゴニストを含む医薬組成物並びにその使用
|
CN102946875A
(zh)
|
2010-05-05 |
2013-02-27 |
贝林格尔.英格海姆国际有限公司 |
组合疗法
|
CA2795105A1
(en)
|
2010-05-05 |
2011-11-10 |
Peter Schneider |
Pharmaceutical formulations comprising pioglitazone and linagliptin
|
EP2585052A4
(en)
|
2010-06-22 |
2014-10-01 |
Twi Pharmaceuticals Inc |
CONTROLLED RELEASE COMPOSITIONS HAVING REDUCED FOOD EFFECT
|
CA2803504C
(en)
|
2010-06-24 |
2022-08-30 |
Boehringer Ingelheim International Gmbh |
A combination for diabetes therapy comprising linagliptin and a long-acting insulin
|
EP2611442B1
(en)
|
2010-09-03 |
2018-07-04 |
Bristol-Myers Squibb Company |
Drug formulations using water soluble antioxidants
|
US20120283169A1
(en)
|
2010-11-08 |
2012-11-08 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
US9034883B2
(en)
|
2010-11-15 |
2015-05-19 |
Boehringer Ingelheim International Gmbh |
Vasoprotective and cardioprotective antidiabetic therapy
|
WO2012088682A1
(en)
|
2010-12-29 |
2012-07-05 |
Shanghai Fochon Pharmaceutical Co Ltd. |
2-(3-aminopiperidin-1-yl)-[1,2,4]triazolo[1,5-c]pyrimidine-5,7(3h,6h)-dione derivates as dipeptidyl peptidase iv(dpp-iv) inhibitors
|
JP2014504639A
(ja)
|
2011-02-01 |
2014-02-24 |
ブリストル−マイヤーズ スクイブ カンパニー |
アミン化合物を含む医薬製剤
|
US20130035281A1
(en)
|
2011-02-09 |
2013-02-07 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
UY33937A
(es)
|
2011-03-07 |
2012-09-28 |
Boehringer Ingelheim Int |
Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina
|
US8785455B2
(en)
|
2011-05-10 |
2014-07-22 |
Sandoz Ag |
Polymorph of linagliptin benzoate
|
CA2837627A1
(en)
|
2011-06-03 |
2012-12-06 |
Boehringer Ingelheim International Gmbh |
Sglt-2 inhibitors for treating metabolic disorders in patients treated with neuroleptic agents
|
US20130035298A1
(en)
|
2011-07-08 |
2013-02-07 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
DK2731947T3
(en)
|
2011-07-15 |
2019-04-23 |
Boehringer Ingelheim Int |
SUBSTITUTED DIMERIC QUINAZOLINE DERIVATIVE, PREPARATION AND USE thereof IN PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF TYPE I AND TYPE II DIABETES
|
DE102011109492A1
(de)
|
2011-08-04 |
2013-02-07 |
GM Global Technology Operations LLC (n. d. Gesetzen des Staates Delaware) |
Fahrunterstützungsvorrichtung zur Unterstützung der Befahrung enger Fahrwege
|
US20130172244A1
(en)
|
2011-12-29 |
2013-07-04 |
Thomas Klein |
Subcutaneous therapeutic use of dpp-4 inhibitor
|
US9139802B2
(en)
|
2012-01-04 |
2015-09-22 |
The Procter & Gamble Company |
Active containing fibrous structures with multiple regions
|
US9555001B2
(en)
|
2012-03-07 |
2017-01-31 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition and uses thereof
|
US9192617B2
(en)
|
2012-03-20 |
2015-11-24 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
EP2849755A1
(en)
|
2012-05-14 |
2015-03-25 |
Boehringer Ingelheim International GmbH |
A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
|
WO2013174768A1
(en)
|
2012-05-24 |
2013-11-28 |
Boehringer Ingelheim International Gmbh |
A xanthine derivative as dpp -4 inhibitor for use in the treatment of autoimmune diabetes, particularly lada
|
WO2013174767A1
(en)
|
2012-05-24 |
2013-11-28 |
Boehringer Ingelheim International Gmbh |
A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
|
WO2013179307A2
(en)
|
2012-05-29 |
2013-12-05 |
Mylan Laboratories Limited |
Stabilized pharmaceutical compositions of saxagliptin
|
WO2014140284A1
(en)
|
2013-03-15 |
2014-09-18 |
Boehringer Ingelheim International Gmbh |
Use of linagliptin in cardio- and renoprotective antidiabetic therapy
|
US20140303097A1
(en)
|
2013-04-05 |
2014-10-09 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
PT2981271T
(pt)
|
2013-04-05 |
2019-02-19 |
Boehringer Ingelheim Int |
Utilizações terapêuticas de empagliflozina
|
WO2014170383A1
(en)
|
2013-04-18 |
2014-10-23 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
EP3007701A1
(en)
|
2013-06-14 |
2016-04-20 |
Boehringer Ingelheim International GmbH |
Dpp-4 inhibitors for treating diabetes and its complications
|
JP6615109B2
(ja)
|
2014-02-28 |
2019-12-04 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Dpp−4阻害薬の医学的使用
|